The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Please provide your email address to receive an email when new articles are posted on . An artificial intelligence-based ECG analysis solution reduced the rate of false-positive atrial fibrillation ...

The Reveal in the Investigation of Syncope and Epilepsy (REVISE) study found that one in eight patients who were previously thought to have epilepsy or in whom this diagnosis was in doubt actually had ...

(MENAFN- GetNews) According to a recent report published by Grand View Research Inc., the growing incidence of cardiac disorders in the geriatric population and high demand for advanced medical ...

Dublin, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The "Implantable Loop Recorders Market Size, Share & Trends Analysis Report By Activation, By Application, By End Use, By Region, And Segment Forecasts, 2025 ...

Please provide your email address to receive an email when new articles are posted on . Implicity announced the FDA cleared its algorithm analyzing ECG data from implantable loop recorders.

Barcelona, Spain, 1 September 2009: The REVISE Study (Reveal in the Investigation of Syncope and Epilepsy) found that 1 in 8 adult patients in the United Kingdom, previously thought to be suffering ...

For the first time in Maharashtra, Nanavati Super Speciality Hospital has inserted implantable loop recorder in a 62-year-old patient from Bangladesh suffering from syncope to track his heart rhythm ...

Dublin, Dec. 18, 2017 (GLOBE NEWSWIRE) -- The "Cardiovascular Disease Monitoring and Diagnostic Devices - Global Strategic Business Report" report has been added to Research and Markets' offering. The ...

According to HTF market Intelligence, the global Implantable Cardiac Loop Recorders market is estimated to grow with a CAGR of 9.19% from 2024 to 2030. Stay up-to-date with Global Implantable Cardiac ...